γ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct

γ‐Secretase inhibitors (GSIs) are being actively repurposed as cancer therapeutics based on the premise that inhibition of NOTCH1 signaling in select cancers is therapeutic. Using novel assays to probe effects of GSIs against a broader panel of substrates, we demonstrate that clinical GSIs are pharm...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:EMBO Mol Med
Egile Nagusiak: Ran, Yong, Hossain, Fokhrul, Pannuti, Antonio, Lessard, Christian B, Ladd, Gabriela Z, Jung, Joo In, Minter, Lisa M, Osborne, Barbara A, Miele, Lucio, Golde, Todd E
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2017
Gaiak:
Research Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5494507/
https://ncbi.nlm.nih.gov/pubmed/28539479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201607265
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak